Global growth investor The Abraaj Group has exited its investment in Tunisia-based pharmaceutical company Unité de Fabrication de Médicaments (Unimed) through an initial public offering (IPO) on the Tunis Stock Exchange. The IPO was priced at TND11.8 (approximately US$5.91) per share, implying a market capitalization of TND300 million (approximately US$150 million). Abraaj originally invested in the company in 2011. Financial details of Abraaj’s exit were not disclosed.